Community acquired pneumonia and treatment options

Community acquired pneumonia and treatment options PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

CAP patient characteristics. Smokers: S. pneumo, H. influenzae, MoraxellaPost viral bronchitis: S. pneumoNo co-morbidity: atypicals, viralAlcoholic: S. pneumo, anaerobesIV drug user: S. aureusEpidemic: Legionnaire'sAirway obstruction: anaerobesAnimals: Psittacosis, Tularemia, Coxiella burneti

Download Presentation

Community acquired pneumonia and treatment options

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

1. Community acquired pneumonia and treatment options 6 mechanisms in pathogenesis of pneumonia – (inhalation, aspiration, direct inoculation, reactivation, defects in pulmonary defenses, blunted cellular or humoral immune response) In general, clinical presentation: pleuritic chest pain, fever, cough, decreased breath sounds, dull to percussion, egophony Classified as “typical” or “atypical” or viral Typical = S. pneumoniae, H. influenza, S. aureus, enteric gram negative bacteria. More segmental or lobar infiltrate. Atypical = Mycoplasma, Legionella, Chlamydia pneumonia. More diffuse infiltrate. Sputum gram stain usually negative. Empiric treatment prior to susceptibility testing- cover S. pneumoniae, S. aureus, H. influenzae. Give amoxicillin-clavulanate, and 2nd or 3rd generation cephalosporin, or respiratory fluoroquinolone (3rd and 4th generation).

2. CAP patient characteristics Smokers: S. pneumo, H. influenzae, Moraxella Post viral bronchitis: S. pneumo No co-morbidity: atypicals, viral Alcoholic: S. pneumo, anaerobes IV drug user: S. aureus Epidemic: Legionnaire’s Airway obstruction: anaerobes Animals: Psittacosis, Tularemia, Coxiella burnetii

3. Mechanisms of action of different antimicrobials Penicillins- Inhibits the transpeptidase enzyme step in peptidoglycan cell wall synthesis 1st generation:[ex Pen G] most streptococci, oral anaerobic coverage 2nd generation:[nafcillin] most streptococci, S. aureus (Penicillinase resistant) 3rd generation:[amoxicillin, ampicillin] most streptococci, basic G – coverage. Amoxicillin is oral DOC for susceptible strains of S. pneumoniae Amoxicillin with clavulanate treats beta lactamase producing bacteria like H. influenzae, Methicillin sensitive Staph aureus and anaerobes 4th generation:[piperacillin] extended spectrum, includes pseudomonas Cephalosporins-inhibits cell wall synthesis Parenteral DOC for CAP caused by susceptible strains of S pneumoniae, H influenzae, Staph aureus. 1st generation: G+ (including Staph aureus), basic G- 2nd generation: G+, diminished Staph aureus, improved G- coverage, some anaerobic coverage 3rd generation: further diminished S. aureus, further improved G-, some Pseudomonal coverage and diminished G+ coverage 4th generation: same as 3rd plus coverage against Pseudomonas **note that neither group is effective against “atypicals”

4. Macroglides-inhibits 50s subunit of ribosome in protein synthesis Treats mycoplasma, legionnaire’s, chlamydial infections Active against most common pathogens and atypical agents. Macroglide resistance is emerging to Strep pneumoniae Fluoroquinolones-inhibits DNA gyrase Broad spectrum against likely agents of CAP. Active against penicillin resistant Strep pneumoniae. Resistance developing. 1st generation: G- NOT pseudomonas, UTI only, NO atypicals 2nd generation: G- including pseudomonas, S. aureus, some atypicals NOT pneumococcus 3rd generation: G-, G+, expanded atypicals 4th generation: same as 3rd plus enhanced coverage of pneumococcus, decreased activity vs pseudomonas. Tetracyclines- inhibits 30s subunit of ribosome in protein synthesis G+ and G-, aerobic & anaerobic bacteria, “atypicals”- mycoplasma, chlamydia and category A bioterrorism agents

5. Streptococcus pneumoniae (2/3 of CAP cases) Properties: G + diplococci “lancet shaped”, a hemolytic. #1 cause CAP: “rusty sputum”, single rigor, fever. Tx and dose: sensitive strains treat with penicillin G 250,000-400,000 units/kg/day IV divided q 4-6 or amoxicillin (oral) 1g PO tid. intermediate resistance strains are susceptible to 2nd/3rd generation parenteral cephalosporins and respiratory fluoroquinolones Cefotaxime 1-2g IM/IV q6-8 or ceftriaxone1-2 g IM/IV q24h. Levofloxicin 500mgIV/po qd (others: alatrofox-, gati-, moxi-) Prevention: capsular vaccines (prevnar, pneumovax)

6. H. influenzae trimethoprim-sulfamethoxazole, Ampicillin IV, Amoxicillin po, azithro/clarithromycin, doxycycline If severe, 3rd gen cephalosporin Enteric gram negatives Anaerobes: clindamycin or beta lactam/beta lactamase inhibitor Staph aureus Sensitive strains: Nafcillin or oxacillin (penicillinase resistant abx) MRSA- Vancomycin Atypicals Legionella- fluroquinolone or azithromycin Mycoplasma- erythro, azithro, clarithromycin, or fluoroquinolone Chlamydia pneumoniae- doxycycline, erythrocyclin or floroquinolones

7. Duration of therapy S pneumoniae: until afebrile for 3-5d C pneumoniae:7-14 d M pneumoniae: not well established. Legionella: 10-21 d S aureus, P aeruginosa, Klebsiella, anaerobes >3weeks

  • Login